Establishment of mouse erythroleukemia cell lines expressing complete Influenza C virus CM2 protein or chimeric protein consisting of CM2 and Influenza A virus M2

Y. MURAKI*, A. HAY

Division of Virology, National Institute for Medical Research, Ridgeway, Mill Hill, London NW7 1AA, UK

Summary. – The role of the Influenza C virus (ICV) CM2 protein in virus replication as well as its precise function as an ion channel remains to be elucidated. For this purpose, we established a CM2-expressing mouse erythroleukemia (MEL) cell line and determined the biochemical characteristics of the expressed CM2. The features of the expressed CM2 were similar to those of the viral CM2 synthesized in ICV-infected cells. Furthermore, we established MEL cell line expressing a chimeric protein consisting of characteristic regions of CM2 and Influenza A virus (IAV) M2 protein that could be helpful in elucidation of the specific ion conductance properties.

Keywords: Influenza C virus; Influenza A virus; CM2 protein; chimeric protein; MEL cells

The genome of ICV consists of 7 single-stranded RNA segments of negative polarity encoding proteins PB2, PB1, P3, hemagglutinin-esterase-fusion (HEF) protein, nucleoprotein (NP), matrix (M1), P42, NS1 and NS2/NEP (Palese and Shaw, 2007). RNA segment 6 containing M1 and P42 gene is 1,180 or 1,181 nts in length. Proteolytic cleavage of P42 at an internal signal peptidase cleavage site gives rise to M1' protein composed of aa 259 and CM2 protein of aa 115 (Yamashita et al., 1988; Hongo et al., 1994, 1998, 1999; Pekosz and Lamb, 1997).

CM2 is abundantly expressed in virus-infected cells and is incorporated into progeny virions as a second membrane protein of the virus (Hongo et al., 1997). CM2 forms a Cl⁻ channel, when expressed in Xenopus laevis oocytes and also has the ability to modulate the pH of the exocytic pathway (Hongo et al., 2004; Betáková and Kollerová, 2006; Betakova and Hay, 2007). However, its role in the virus replication as well as its precise function as the ion channel remains to be elucidated.

The IAV M2 protein, the counterpart of CM2, has been shown to have a role in two stages of virus replication (Palese and Shaw, 2007). During endocytosis, M2 in the virus membrane acts by mediating proton transfer into the virion interior to promote an acid-induced dissociation of the matrix protein from the ribonucleoprotein (RNP). In particular avian influenza virus infections, the M2 equilibrates the pH between the lumen of trans-Golgi network and the cytoplasm, preventing the acidification of the newly synthesized hemagglutinin that is cleaved intracellularly. Recently, the cytoplasmic tail of M2 has been demonstrated to play a role in the incorporation of the RNP into virions (McCown and Pekosz, 2005; Iwatsuki-Horimoto et al., 2006).

Ion permeability due to M2 measured by direct electrophysiological analyses has been reported in several studies employing X. laevis oocytes, CV-1 cells, phospholipid bilayers or MEL cells (Ogden et al., 1998). In all studies, M2 formed an ion channel permeable to protons, which provided the basis for the putative role of M2 in the virus replication.
MEL cells were of significant use in analyzing the precise ion channel activity of M2, because they have a low intrinsic membrane ion permeability and their small size permits control of the ionic composition of cell interior (Shelton et al., 1993). The M2 protein expressed in MEL cells was shown to form an ion channel that selectively transfers protons across the membrane (Chizhmakov et al., 1996).

Construction of cells constitutively expressing a virus protein may also be applicable to rescuing recombinant viruses lacking the protein being expressed (McCown and Pekosz, 2005; Iwatsuki-Horimoto et al., 2006). Recently, MDCK cells expressing the BM2 protein were used to complement a BM2-deficient recombinant of Influenza B virus (Imai et al., 2004). In these studies, the respective roles of M2 and BM2 in the replication of the IAV and influenza B viruses were clarified.

In the present study, we report the successful construction of a CM2-expressing MEL cell clone and present the biochemical characteristics of the expressed CM2 protein. Furthermore, we constructed a MEL cell line expressing chimeric protein consisting of particular regions of CM2 of ICV and M2 of IAV. The transmembrane (TM) region of M2 was replaced with that of CM2. Also, we analyzed the biochemical properties of the chimeric protein.

Initially, we attempted to establish MEL cell clones expressing the CM2 protein of the ICV strain C/YA/1/88 (Acc. No. D16261) (Hongo et al., 1994). We cloned a methionine (Met)-CM2 cDNA, where an initiation codon (ATG) was added to the 5'-end of CM2-ORF, and inserted in pEV3 vector at the EcoRI and BglII sites. The resulting plasmid was linearized and transfected into MEL cells as described previously (Chizhmakov et al., 1996; Ogden et al., 1998). The transfected MEL cells were cultured for 10–14 days in the presence of geneticin until the drug-resistant MEL cells became 50% confluent. Single MEL cell clones were obtained by limiting dilution in a 96-well plate and subsequently maintained in the presence of geneticin. The level of CM2 expression by individual clones was analyzed by Western blot analysis.

The MEL cell clone (MEL/CM2) expressed a considerable amount of CM2 as detected using anti-CM2 serum (ACS) (Fig. 1) (Hongo et al., 1994). The optimal conditions for CM2 expression in the MEL/CM2 were determined as described previously (Ogden et al., 1998). At the optimal induction concentration (2%) of dimethyl sulfoxide (DMSO), CM2 expression was comparable to that as in ICV-infected HMV-II cells, a human melanoma cell line highly susceptible to ICV (Nishimura et al., 1989) (Fig. 1). The CM2 protein accumulated to a maximum level at 3–4 days after induction with DMSO (data not shown). Since expression of CM2 was comparable to that of M2 in a MEL cell clone expressing IAV M2 (MEL/M2-39) (Chizhmakov et al., 1996; Ogden et al., 1998), we concluded that the MEL/CM2 was suitable for the subsequent analyses of the biochemical properties of CM2.

We examined glycosylation, phosphorylation, acylation, and tetramer formation of the CM2 expressed in the MEL cells. At day 4 post induction, the MEL/CM2 cells were labeled with [35S]-methionine for 30 mins and then chased for 2 hrs. Cell lysates were prepared either immediately after the pulse or after the chase and immunoprecipitated with
The precipitates were digested with various endoglycosidases and then analyzed by SDS-PAGE and processed for fluorography (Yokota et al., 1983; Hongo et al., 1997). N-glycanase converted CM2a and CM2b to non-glycosylated form of CM2 (CM2o) (Fig. 2). CM2a was sensitive to digestion with endo H, whereas CM2b was resistant. On the other hand, CM2b was sensitive to endo-β-galactosidase treatment. Taken together, these data indicated that CM2 in MEL cells was modified with polylactosaminoglycans. Previously, Pekosz et al. (1997) reported that CM2b expressed in both MDCK and HeLa-T4 cells was sensitive to endo-β-galactosidase treatment, whereas Hongo et al. (1997) reported that CM2b in ICV-infected HMV-II cells was resistant to that treatment. Thus, the glycosylation machinery on CM2 appears to vary according to the cell line used.

The induced MEL/CM2 cells were labeled also with [32P]orthophosphate or [3H]-palmitic acid and immunoprecipitated with ACS or the cell lysates were analyzed by Western blot analysis under non-reducing conditions (Hongo et al., 1997; Tada et al., 1998). The results showed that CM2 was phosphorylated, acylated, and formed tetramers (data not shown). Thus, except for glycosylation in some cell lines, the posttranslational modifications of CM2 in the MEL cells were similar to those in ICV-infected cells.

Next, the cell surface expression of the CM2 was investigated. CM2 was previously shown to be transported...
to the cell surface using immunofluorescence techniques (Hongo et al., 1997; Pekosz et al., 1997; Li et al., 2001). In the present study, we labeled cell surface proteins with Sulfo-NHS-Biotin (Pierce) and detected the labeled CM2 protein by Western blot analysis, since in the immunofluorescence analysis of MEL cells we detected a high background signals using ACS (data not shown). Induced MEL/CM2 cells or C/YA/1/88-infected HMV-II cells were subjected to Western blot analysis using ACS or anti-HEF monoclonal antibody S16 (Sugawara et al., 1993; Muraki et al., 1999). Both CM2b and HEF protein were detected on the surface of C/YA/1/88-infected HMV-II cells (Fig. 3). Furthermore, a 22–30 K protein was detected on the surface of the MEL cells indicating that CM2b was transported to the plasma membrane (Fig. 3).

Lastly, we established a MEL cell clone (MEL/M2/CM2) expressing an M2/CM2 chimeric protein. The chimeric protein was composed of the M2 extracellular domain (24 aa), the CM2 TM domain (23 aa) and the M2 cytoplasmic domain (54 aa). The expressed chimeric protein was shown to be phosphorylated, acylated, and oligomerized as a homotetramer (data not shown). Flow cytometry analysis using antisera against the M2 extracellular domain revealed that the protein was transported to the cell surface at a similar level as M2 in the MEL/M2-39 cells (Smith et al., 2002) (Fig. 4).

Preliminary electrophysiological studies of CM2-expressing MEL/CM2 cells have identified Na⁺-activated proton permeability in addition to the low pH-activated Cl⁻ permeability (I.V. Chizhmakov, D.C. Ogden, A. Hay, personal communications). The H⁺-activated H⁺-selective permeability of the M2 channel is mainly attributable to the TM domain. Studies of the chimeric protein could help in the elucidation if both activities are intrinsic properties of CM2 or are due to the activation of an endogenous channel.

In conclusion, we reported here the successful establishment of MEL cell clones expressing CM2 and M2/CM2 proteins, which could be used in detailed studies to define the properties of the CM2 ion channel and to rescue CM2-deficient mutants of ICV.

Acknowledgements. We thank Seti Grambas, Michael Bennett, and the members of the Department of Infectious Diseases, Yamagata University for their assistance. This work was supported by a grant-in-aid from the Japan Health Sciences Foundation, Daiwa Anglo-Japanese Foundation, Wellcome Trust, Medical Research Council, Takeda Science Foundation, and Terumo Lifescience Foundation.

References


